Navigation Links
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Date:12/10/2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current therapies.

Dr. Berenson has more than 20 years of senior management experience in biotechnology, and was most recently an Entrepreneur in Residence at the University of Washington. He previously co-founded and served as President and CEO of HemaQuest Pharmaceuticals during the company's first three years, successfully ushering the company's programs into early clinical development of its lead compounds. His background also includes senior executive roles at numerous oncology-focused biotechnology companies, including Founder, Director, President and CEO of Xcyte Therapies, Inc. (which merged with Cyclacel), and Founder, Director, Executive Vice President, Chief Medical Officer and Chief Scientific Officer for CellPro, Inc. (CellPro). At CellPro, he was responsible for regulatory submissions that resulted in the U.S. Food and Drug Administration's (FDA) approval of CellPro's lead product, which was the first FDA-approved biological product in cell therapy. Since 2001, he has been on the Board of Ambassadors of the Fred Hutchinson Cancer Center. Dr. Berenson also has contributed to over 90 publications and holds 10 US patents. He completed his oncology training at Stanford University Medical Center, M.D. from Yale Medical School and obtained his B.S. from Stanford University.

"There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and co
'/>"/>

SOURCE Aequus BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
3. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
10. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2008 Genta,Incorporated (Nasdaq: GNTA ) announced ... Company,s lead anticancer,compound will be featured at the ... (AACR). The meeting will be held in San ... of several abstracts, which are,relevant to both the ...
... 4, 2008 VIA,Pharmaceuticals (Nasdaq: VIAP ), ... for the treatment of cardiovascular disease,announced today that ... VIA-2291 Phase 2 clinical trial program recently met ... studies. The DSMB observed a,continued acceptable safety profile ...
Cached Medicine Technology:Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 2Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 2VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 4
(Date:7/10/2014)... News) -- Teens who are sensitive to light or ... emotional symptoms such as anxiety and depression, a new ... may exacerbate issues teens experience after concussion may help ... decisions about when to return to play and what ... authors Lisa Koehl and Dong Han, of the University ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... regularly between outspoken celebrities or loudmouth pundits -- too much ... study suggests. High amounts of Twitter use can lead ... in a long-term relationship, according to findings from an online ... can lead to cheating and breakups, the researchers concluded, although ...
(Date:7/10/2014)... responders felt better prepared to respond to an active ... a new study in the journal Prehospital and ... specifically examine the EMS provider comfort level with respect ... yet been neutralized or working with law enforcement personnel ... High School shooting, the Virginia Tech campus shooting, the ...
(Date:7/10/2014)... PHILADELPHIA Reducing the amount of alcoholic beverages ... health, including a reduced risk of coronary heart ... pressure, according to a new multi-center study published ... the Perelman School of Medicine at the University ... previous studies which suggest that consuming light-to-moderate amounts ...
(Date:7/10/2014)... Department of Health and Human Services (HHS) has announced ... Center Seidman Cancer Center totaling $4.7 million to support ... patients with complex cancer. , Titled "Evidence-Conformant Oncology ... at UH to enhance care for adult cancer patients ... high health care utilization. , "We believe ...
Breaking Medicine News(10 mins):Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3
... 17 (HealthDay News) -- Children with bipolar disorder and ... time looking at the eyes when trying to identify ... researchers say. This new study finding may help ... dysregulation have difficulty determining other people,s emotional expressions, said ...
... 17, 2011 -- Factors such as low hemoglobin levels, increased ... higher risk of silent cerebral infarcts (SCIs), or silent strokes, ... from a large, first-of-its-kind study published online today ... the American Society of Hematology (ASH). Silent strokes ...
... (HealthDay News) -- Most people who join gangs have ... that challenges previous research suggesting gang membership is driven ... an antisocial personality are impulsive, lack self-discipline and self-control, ... this, they may be excluded from groups at school ...
... increasingly common, and a dangerous lack of new infection ... than ever to use existing antibiotics appropriately. This week, ... care providers, and policymakers about when antibiotics can help, ... harm than good, and the tremendous need for new ...
... that keep blood vessels open to treat heart disease ... in the Journal of Interventional Cardiology . A ... Grines, of the Detroit Medical Center Cardiovascular Institute, and ... attack after the recently marketed Ion stent (Boston Scientific, ...
... InDevR, a Boulder-based biotechnology company that develops advanced ... viruses and other microorganisms, announced today the launch ... colorimetric detection system that incorporates core technology licensed ... will enhance laboratories around the world by offering ...
Cached Medicine News:Health News:Bipolar Kids May Focus on Different Facial Features 2Health News:Study identifies 'silent' stroke risk factors for children with sickle cell anemia 2Health News:Preserving lifesaving antibiotics today and for the future 2Health News:Indevr launches breakthrough colorimetric detection for microarrays using core technology from CU 2
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: